Long-acting injectable HIV prevention for men in France
Part of Infections clinical trials.
This trial tests a long-acting injectable form of HIV prevention (cabotegravir) vs. continuing daily PrEP pills. It is for cisgender men in France who have sex with men and have already been using PrEP for at least 6 months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a cisgender man who has sex with men, age 18 or older.
- You must have taken oral PrEP (Truvada or similar) by prescription in the last 6 months (daily or on-demand).
- You must be willing to be contacted by phone or email and have French social security coverage.
- You must test negative for HIV and have no symptoms of acute HIV infection.
- You cannot have a history of seizures, certain liver or kidney problems, or take certain medications (like rifampin, some anticonvulsants, or blood thinners).
- You must not be planning a trip of more than 2 months outside the Ile de France region during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests how well and how safely an HIV prevention pill (TAF/FTC) works when it’s taken around sexual events. It aims to find a prevention option that’s effective and acceptable for men who have sex with men at higher risk of HIV.
This Phase 3 study tests whether an injectable HIV prevention medicine (cabotegravir) given before exposure can help prevent HIV in people at higher risk. You may join if you are HIV-negative and meet specific sexual health, medication, and health-testing requirements.
This study gives long-acting cabotegravir injections (a shot every 2 months) to people at high risk of HIV. It aims to see if this new prevention method works well in real-world settings.
This study offers a new injectable medication called lenacapavir to prevent HIV. It is for people who are HIV-negative and sexually active, and want to try a long-acting injection instead of daily pills.
This study tests a long-acting HIV prevention shot (Cabotegravir) or a vaginal ring (DapiRing) along with sexual health services for young people. It aims to find the best way to prevent HIV and support overall health.
This study tests a long-acting injectable medication called cabotegravir to prevent HIV in people who inject drugs. If you have injected street drugs recently, you may be able to get this shot every few months instead of taking daily pills.
Hear when a new Prevention trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.